On October 31, 2022 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, reported that the company will participate in the Sidoti November Virtual Micro-Cap Conference on November 9, 2022 (Press release, Akari Therapeutics, OCT 31, 2022, View Source [SID1234622634]). President and CEO Rachelle Jacques will present a company overview at 1:45 pmEastern time and the management team will attend scheduled 1:1 investor meetings. Investors registered for the conference may schedule 1:1 meetings with Akari through the Sidoti conference website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A recording will be available at akaritx.com following the company presentation.